AbbVie Says Rinvoq Gets FDA OK For Ulcerative Colitis

AbbVie announced that the U.S. FDA has approved rinvoq (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more tumor necrosis factor TNF blockers.

• FDA approval is the first indication for rinvoq in gastroenterology and is supported by efficacy and safety data from three Phase 3 randomized, double-blind, placebo-controlled clinical studies

NOTE

• AbbVie Inc. rose 0.3% in postmarket trading to $156.48 as of 5:31 p.m. New York time
  • The average 12-month price target of $152.55 is 2.5% below the current price
  • 18 buys, 7 holds, ...